These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9141478)

  • 1. Comparison of the amide proton exchange behavior of the rapidly formed folding intermediate and the native state of an antibody scFv fragment.
    Freund C; Gehrig P; Holak TA; Plückthun A
    FEBS Lett; 1997 Apr; 407(1):42-6. PubMed ID: 9141478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folding nuclei of the scFv fragment of an antibody.
    Freund C; Honegger A; Hunziker P; Holak TA; Plückthun A
    Biochemistry; 1996 Jun; 35(25):8457-64. PubMed ID: 8679604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct evidence by H/D exchange and ESI-MS for transient unproductive domain interaction in the refolding of an antibody scFv fragment.
    Jäger M; Plückthun A
    Protein Sci; 2000 Mar; 9(3):552-63. PubMed ID: 10752617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel pathways in the folding of a short-term denatured scFv fragment of an antibody.
    Freund C; Gehrig P; Baici A; Holak TA; Plückthun A
    Fold Des; 1998; 3(1):39-49. PubMed ID: 9502319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment.
    Nieba L; Honegger A; Krebber C; Plückthun A
    Protein Eng; 1997 Apr; 10(4):435-44. PubMed ID: 9194169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate-limiting steps for the folding of an antibody scFv fragment.
    Jäger M; Plückthun A
    FEBS Lett; 1997 Nov; 418(1-2):106-10. PubMed ID: 9414105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiferritin single-chain Fv fragment is a functional protein with properties of a partially structured state: comparison with the completely folded V(L) domain.
    Martsev SP; Chumanevich AA; Vlasov AP; Dubnovitsky AP; Tsybovsky YI; Deyev SM; Cozzi A; Arosio P; Kravchuk ZI
    Biochemistry; 2000 Jul; 39(27):8047-57. PubMed ID: 10891087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen.
    Jäger M; Plückthun A
    J Mol Biol; 1999 Feb; 285(5):2005-19. PubMed ID: 9925781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation.
    Ramm K; Gehrig P; Plückthun A
    J Mol Biol; 1999 Jul; 290(2):535-46. PubMed ID: 10390351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria.
    Jäger M; Plückthun A
    FEBS Lett; 1999 Dec; 462(3):307-12. PubMed ID: 10622716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equilibrium amide hydrogen exchange and protein folding kinetics.
    Bai Y
    J Biomol NMR; 1999 Sep; 15(1):65-70. PubMed ID: 10549134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy.
    Freund C; Ross A; Plückthun A; Holak TA
    Biochemistry; 1994 Mar; 33(11):3296-303. PubMed ID: 8136365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scFv fragment of the antibody hu4D5-8: evidence for early premature domain interaction in refolding.
    Jäger M; Gehrig P; Plückthun A
    J Mol Biol; 2001 Feb; 305(5):1111-29. PubMed ID: 11162118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermal unfolding of a llama antibody fragment: a two-state reversible process.
    Pérez JM; Renisio JG; Prompers JJ; van Platerink CJ; Cambillau C; Darbon H; Frenken LG
    Biochemistry; 2001 Jan; 40(1):74-83. PubMed ID: 11141058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface.
    Vranken W; Tolkatchev D; Xu P; Tanha J; Chen Z; Narang S; Ni F
    Biochemistry; 2002 Jul; 41(27):8570-9. PubMed ID: 12093273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
    Wörn A; Plückthun A
    Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilization of native protein fold by intein-mediated covalent cyclization.
    Williams NK; Liepinsh E; Watt SJ; Prosselkov P; Matthews JM; Attard P; Beck JL; Dixon NE; Otting G
    J Mol Biol; 2005 Mar; 346(4):1095-108. PubMed ID: 15701520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
    Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
    Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.